safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Articles by safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 Vaccination Linked to Lower Risk of Long COVID in Adolescents
2
Nearly All US Youth With BMI-Defined Obesity Have Excess Adiposity
3
Remote Monitoring May Improve Heart Failure Outcomes: Anitha Vijayan, MD
4
GLP-1 for Treatment of Heart Failure
5
